AAV-DJ MBP eGFP particles transduce enhanced Green Fluorescent Protein (eGFP) under the control of a 1.3 Kb MBP (myelin basic protein) promoter that drives GFP reporter expression in oligodendrocytes.
●
Product Data Gallery
Purified AAV-DJ MBP eGFP particles.
Transduction of HEK293 cells with AAV-DJ MBP eGFP particles.
Two vials (50 µl x 2) of AAV at a titer ≥1 x 1012 vector genomes/ml. The titer is determined by qPCR and varies with each lot; the exact value will be provided with each shipment.
Purification
The purity of the AAV particles was confirmed to be greater than 90% by staining with One-Step Lumitein™ UV Protein Gel Stain (Biotium, 21005-1L). The purity varies with each lot; the exact value will be provided with each shipment.
Formulation
AAV was produced in HEK293-AAV cells and is supplied in PBS-MK (PBS Magnesium-Potassium) buffer containing 0.01% Pluronic F68. Virus particles can be packaged in custom formulations by special request, for an additional fee.
Background
Adeno-Associated Virus-DJ (AAV-DJ) is a synthetic serotype made from eight different wild-type AAV serotypes (AAV2, 4, 5, 8, 9, avian, bovine, and goat AAV) using DNA shuffling. These modifications allow the AAV-DJ serotype to exhibit improved transduction efficiency in vitro and in vivo and infect a broader range of cell types compared to the wild-type serotypes.
Myelin basic protein (MBP) is an oligodendrocyte-specific protein that interacts with the cell cytoskeleton and participates in oligodendrocyte differentiation by ensuring proper compaction of the myelin sheath. The use of a MBP promoter allows specific expression of proteins in this essential cell type of the central nervous system.
Storage/Stability
AAV is shipped with dry ice. For long-term storage, it is recommended to store AAV at -80°C for up to 12 months from date of receipt. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle
Applications
Positive control in oligodendrocyte transduction.
Optimization of transduction assays and tracking of transgene expression over time.
Shipping Temperature
-80°C
Notes
The AAV-DJ viruses are covered under several patents, including U.S. Patent Nos. 7,588,772, 8,067,014, 8,574,583, and 8,906,387, as well as corresponding foreign patents applications and patent rights. AAV-DJ is used under a license agreement.
Biosafety Recombinant AAV is inherently replication-deficient and not known to cause any human diseases. Additionally, following transduction, AAV vectors exist episomally and do not integrate into or disrupt the host cell’s genome. AAV requires the use of a Biosafety Level 1 facility. BPS Bioscience recommends following all local, federal, state, and institutional regulations and using all appropriate safety precautions
Powered by Bioz
